Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01757418 · ClinicalTrials.gov registry record · Phase 1
Intravenous Gammaglobulin for Sickle Cell Pain Crises
A Phase 1 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
NCT01757418: Completed Phase 1 study, sponsored by Albert Einstein College of Medicine.
NCT01757418 is a Phase 1 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 300 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (400% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01757418, a Phase 1 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is safe and effective in the acute treatment of pain crises in sickle cell disease. Funding Source: Food and Drug Administration (FDA), Office of Orphan Products Development (OOPD)
Primary Outcome
Length (duration) of vaso-occlusive crisis as measured from the time of presentation to the emergency room to end of VOC defined as 12 hours from the last dose of parenteral opioid analgesia for the treatment of VOC prior to hospital discharge. Group results will be summarized in number of days using univariate statistics.
Interventions
- OTHER Normal saline
- DRUG Immune Globulin Intravenous (IVIG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2008-11 |
| Est. Completion | 2024-12-18 |
| Phase | Phase 1 |
What the finished NCT01757418 record still lists
NCT01757418 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (400% higher).
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT01757418 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01757418 about?
NCT01757418 is a clinical study titled "Intravenous Gammaglobulin for Sickle Cell Pain Crises". The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is safe and effective in the acute treatment of pain crises in sickle cell disease. Funding Source: Food and Drug Administration (FDA), Office of Orphan Products Development (OOPD)
What is the current status of trial NCT01757418?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2008-11. Estimated completion is 2024-12-18.
What interventions are being tested in trial NCT01757418?
The interventions under investigation include: Normal saline (OTHER), Immune Globulin Intravenous (IVIG) (DRUG).
Who is sponsoring clinical trial NCT01757418?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01757418's enrollment target sits among peer trials
300 124th of 2000 higher than 1,867 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia